Fulcrum Therapeutics, Inc.
FULC
$6.67
$0.152.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -3.11% | 14.44% | |||
| Gross Profit | 3.11% | -14.44% | |||
| SG&A Expenses | -2.44% | -9.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.88% | 5.01% | |||
| Operating Income | 2.88% | -5.01% | |||
| Income Before Tax | 2.03% | -6.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.03% | -6.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.03% | -6.56% | |||
| EBIT | 2.88% | -5.01% | |||
| EBITDA | 2.89% | -5.19% | |||
| EPS Basic | 2.16% | 7.98% | |||
| Normalized Basic EPS | 2.15% | 7.97% | |||
| EPS Diluted | 0.92% | 8.87% | |||
| Normalized Diluted EPS | 2.15% | 7.97% | |||
| Average Basic Shares Outstanding | 0.10% | 15.80% | |||
| Average Diluted Shares Outstanding | 0.10% | 15.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||